195 related articles for article (PubMed ID: 36862168)
1. Daratumumab plus bortezomib, cyclophosphamide, and dexamethasone in Asian patients with newly diagnosed AL amyloidosis: subgroup analysis of ANDROMEDA.
Suzuki K; Wechalekar AD; Kim K; Shimazaki C; Kim JS; Ikezoe T; Min CK; Zhou F; Cai Z; Chen X; Iida S; Katoh N; Fujisaki T; Shin HJ; Tran N; Qin X; Vasey SY; Tromp B; Weiss BM; Comenzo RL; Kastritis E; Lu J
Ann Hematol; 2023 Apr; 102(4):863-876. PubMed ID: 36862168
[TBL] [Abstract][Full Text] [Related]
2. Health-related quality of life in patients with light chain amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone ± daratumumab: Results from the ANDROMEDA study.
Sanchorawala V; Palladini G; Minnema MC; Jaccard A; Lee HC; Gibbs S; Mollee P; Venner C; Lu J; Schönland S; Gatt M; Suzuki K; Kim K; Cibeira MT; Beksac M; Libby E; Valent J; Hungria V; Wong SW; Rosenzweig M; Bumma N; Chauveau D; Gries KS; Fastenau J; Tran NP; Qin X; Vasey SY; Weiss BM; Vermeulen J; Ho KF; Merlini G; Comenzo RL; Kastritis E; Wechalekar AD
Am J Hematol; 2022 Jun; 97(6):719-730. PubMed ID: 35293006
[TBL] [Abstract][Full Text] [Related]
3. Outcomes by Cardiac Stage in Patients With Newly Diagnosed AL Amyloidosis: Phase 3 ANDROMEDA Trial.
Minnema MC; Dispenzieri A; Merlini G; Comenzo RL; Kastritis E; Wechalekar AD; Grogan M; Witteles R; Ruberg FL; Maurer MS; Tran N; Qin X; Vasey SY; Weiss BM; Vermeulen J; Jaccard A
JACC CardioOncol; 2022 Nov; 4(4):474-487. PubMed ID: 36444227
[TBL] [Abstract][Full Text] [Related]
4. Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA.
Palladini G; Kastritis E; Maurer MS; Zonder J; Minnema MC; Wechalekar AD; Jaccard A; Lee HC; Bumma N; Kaufman JL; Medvedova E; Kovacsovics T; Rosenzweig M; Sanchorawala V; Qin X; Vasey SY; Weiss BM; Vermeulen J; Merlini G; Comenzo RL
Blood; 2020 Jul; 136(1):71-80. PubMed ID: 32244252
[TBL] [Abstract][Full Text] [Related]
5. Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.
Kastritis E; Palladini G; Minnema MC; Wechalekar AD; Jaccard A; Lee HC; Sanchorawala V; Gibbs S; Mollee P; Venner CP; Lu J; Schönland S; Gatt ME; Suzuki K; Kim K; Cibeira MT; Beksac M; Libby E; Valent J; Hungria V; Wong SW; Rosenzweig M; Bumma N; Huart A; Dimopoulos MA; Bhutani D; Waxman AJ; Goodman SA; Zonder JA; Lam S; Song K; Hansen T; Manier S; Roeloffzen W; Jamroziak K; Kwok F; Shimazaki C; Kim JS; Crusoe E; Ahmadi T; Tran N; Qin X; Vasey SY; Tromp B; Schecter JM; Weiss BM; Zhuang SH; Vermeulen J; Merlini G; Comenzo RL;
N Engl J Med; 2021 Jul; 385(1):46-58. PubMed ID: 34192431
[TBL] [Abstract][Full Text] [Related]
6. Daratumumab: A Review in Newly Diagnosed Systemic Light Chain Amyloidosis.
Blair HA
Drugs; 2022 Apr; 82(6):683-690. PubMed ID: 35416593
[TBL] [Abstract][Full Text] [Related]
7. Impact of cytogenetic abnormalities on treatment outcomes in patients with amyloid light-chain amyloidosis: subanalyses from the ANDROMEDA study.
Kumar S; Dispenzieri A; Bhutani D; Gertz M; Wechalekar A; Palladini G; Comenzo R; Fonseca R; Jaccard A; Kastritis E; Schönland S; la Porte C; Pei H; Tran N; Merlini G
Amyloid; 2023 Sep; 30(3):268-278. PubMed ID: 36779691
[TBL] [Abstract][Full Text] [Related]
8. Adding Cyclophosphamide to Bortezomib and Dexamethasone was not Associated With Improved Outcomes of Patients With Newly Diagnosed Light Chain Amyloidosis: A Retrospective Study.
Zhang Y; Duncanson L; Brayer J; Reu F; Hansen D; Alsina M; Nishihori T; Ochoa-Bayona J; Liu H; Shain K; Thompson Z; Baz R; Blue B
Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):e770-e776. PubMed ID: 35504808
[TBL] [Abstract][Full Text] [Related]
9. Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study.
Yimer H; Melear J; Faber E; Bensinger WI; Burke JM; Narang M; Stevens D; Gunawardena S; Lutska Y; Qi K; Ukropec J; Qi M; Lin TS; Rifkin RM
Br J Haematol; 2019 May; 185(3):492-502. PubMed ID: 30828799
[TBL] [Abstract][Full Text] [Related]
10. Population Pharmacokinetics and Exposure-Response Modeling of Daratumumab Subcutaneous Administration in Patients With Light-Chain Amyloidosis.
Luo MM; Zhu PP; Nnane I; Xiong Y; Merlini G; Comenzo RL; Kastritis E; Wechalekar AD; Weiss BM; Tran N; Qin X; Vermeulen J; Sharma A; Sun YN; Zhou H
J Clin Pharmacol; 2022 May; 62(5):656-669. PubMed ID: 34708423
[TBL] [Abstract][Full Text] [Related]
11. Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial.
Moreau P; Hulin C; Perrot A; Arnulf B; Belhadj K; Benboubker L; Béné MC; Zweegman S; Caillon H; Caillot D; Corre J; Delforge M; Dejoie T; Doyen C; Facon T; Sonntag C; Fontan J; Mohty M; Jie KS; Karlin L; Kuhnowski F; Lambert J; Leleu X; Macro M; Orsini-Piocelle F; Roussel M; Stoppa AM; van de Donk NWCJ; Wuillème S; Broijl A; Touzeau C; Tiab M; Marolleau JP; Meuleman N; Vekemans MC; Westerman M; Klein SK; Levin MD; Offner F; Escoffre-Barbe M; Eveillard JR; Garidi R; Ahmadi T; Krevvata M; Zhang K; de Boer C; Vara S; Kampfenkel T; Vanquickelberghe V; Vermeulen J; Avet-Loiseau H; Sonneveld P
Lancet Oncol; 2021 Oct; 22(10):1378-1390. PubMed ID: 34529931
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of dose-attenuated bortezomib, cyclophosphamide and dexamethasone ("VCD-Lite") in very old or otherwise toxicity-vulnerable adults with newly diagnosed multiple myeloma.
Tuchman SA; Moore JO; DeCastro CD; Li Z; Sellars E; Kang Y; Long G; Gasparetto CG
J Geriatr Oncol; 2017 May; 8(3):165-169. PubMed ID: 28256432
[TBL] [Abstract][Full Text] [Related]
13. First report of outcomes in patients with stage IIIb AL amyloidosis treated with Dara-VCD front-line therapy.
Chakraborty R; Rosenbaum C; Kaur G; Bhutani D; Radhakrishnan J; Mapara MY; Maurer M; Lentzsch S
Br J Haematol; 2023 Jun; 201(5):913-916. PubMed ID: 36896578
[TBL] [Abstract][Full Text] [Related]
14. Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Chinese Patients with Relapsed or Refractory Multiple Myeloma: Phase 3 LEPUS (MMY3009) Study.
Lu J; Fu W; Li W; Hu J; An G; Wang Y; Fu C; Chen L; Jin J; Cen X; Ge Z; Cai Z; Niu T; Qi M; Sun S; Gai X; Liu W; Liu W; Yang X; Huang X
Clin Lymphoma Myeloma Leuk; 2021 Sep; 21(9):e699-e709. PubMed ID: 34108127
[TBL] [Abstract][Full Text] [Related]
15. Daratumumab Plus Bortezomib and Dexamethasone in Newly Diagnosed Systemic Light Chain Amyloidosis.
Kennedy VE; Natsuhara K; Maringanti SA; Shah ND; Arora S; Wolf J; Martin TG; Aras MA; Chung A; Wong SW
Curr Probl Cancer; 2023 Jun; 47(3):100953. PubMed ID: 36807996
[TBL] [Abstract][Full Text] [Related]
16. Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma: matching-adjusted indirect comparison.
Moreau P; Hebraud B; Facon T; Leleu X; Hulin C; Hashim M; Hu Y; Caillot D; Benboubker L; Zweegman S; Merz M; Weisel K; Salwender H; Mai EK; Goldschmidt H; Bertsch U; Vanquickelberghe V; Kampfenkel T; Boer C; Krotneva S; Proskorovsky I; He J; Lam A; Lee C; Cote S; Sonneveld P
Immunotherapy; 2021 Feb; 13(2):143-154. PubMed ID: 33228440
[No Abstract] [Full Text] [Related]
17. Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.
Palumbo A; Chanan-Khan A; Weisel K; Nooka AK; Masszi T; Beksac M; Spicka I; Hungria V; Munder M; Mateos MV; Mark TM; Qi M; Schecter J; Amin H; Qin X; Deraedt W; Ahmadi T; Spencer A; Sonneveld P;
N Engl J Med; 2016 Aug; 375(8):754-66. PubMed ID: 27557302
[TBL] [Abstract][Full Text] [Related]
18. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.
Gay F; Musto P; Rota-Scalabrini D; Bertamini L; Belotti A; Galli M; Offidani M; Zamagni E; Ledda A; Grasso M; Ballanti S; Spadano A; Cea M; Patriarca F; D'Agostino M; Capra A; Giuliani N; de Fabritiis P; Aquino S; Palmas A; Gamberi B; Zambello R; Petrucci MT; Corradini P; Cavo M; Boccadoro M
Lancet Oncol; 2021 Dec; 22(12):1705-1720. PubMed ID: 34774221
[TBL] [Abstract][Full Text] [Related]
19. Successful treatment of renal light chain (AL) amyloidosis with bortezomib and dexamethasone (VD).
Huang B; Li J; Xu X; Zheng D; Zhou Z; Liu J
Pathol Biol (Paris); 2015 Feb; 63(1):17-20. PubMed ID: 25455933
[TBL] [Abstract][Full Text] [Related]
20. Daratumumab, Bortezomib, and Dexamethasone versus Bortezomib and Dexamethasone in Chinese Patients With Relapsed or Refractory Multiple Myeloma: Updated Analysis of LEPUS.
Fu W; Li W; Hu J; An G; Wang Y; Fu C; Chen L; Jin J; Cen X; Ge Z; Cai Z; Niu T; Qi M; Gai X; Li Q; Liu W; Liu W; Yang X; Chen X; Lu J
Clin Lymphoma Myeloma Leuk; 2023 Jan; 23(1):e51-e58. PubMed ID: 36402700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
